JP2021532829A5 - - Google Patents

Info

Publication number
JP2021532829A5
JP2021532829A5 JP2021528490A JP2021528490A JP2021532829A5 JP 2021532829 A5 JP2021532829 A5 JP 2021532829A5 JP 2021528490 A JP2021528490 A JP 2021528490A JP 2021528490 A JP2021528490 A JP 2021528490A JP 2021532829 A5 JP2021532829 A5 JP 2021532829A5
Authority
JP
Japan
Prior art keywords
cells
antibody
cell population
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021528490A
Other languages
English (en)
Japanese (ja)
Other versions
JP7565271B2 (ja
JP2021532829A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/070125 external-priority patent/WO2020021045A2/en
Publication of JP2021532829A publication Critical patent/JP2021532829A/ja
Publication of JP2021532829A5 publication Critical patent/JP2021532829A5/ja
Priority to JP2024170336A priority Critical patent/JP7906202B2/ja
Application granted granted Critical
Publication of JP7565271B2 publication Critical patent/JP7565271B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021528490A 2018-07-26 2019-07-25 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法 Active JP7565271B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024170336A JP7906202B2 (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862703654P 2018-07-26 2018-07-26
US62/703,654 2018-07-26
PCT/EP2019/070125 WO2020021045A2 (en) 2018-07-26 2019-07-25 Therapeutic preparations of gamma-delta t cells and natural killer cells and methods for manufacture and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024170336A Division JP7906202B2 (ja) 2018-07-26 2024-09-30 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Publications (3)

Publication Number Publication Date
JP2021532829A JP2021532829A (ja) 2021-12-02
JP2021532829A5 true JP2021532829A5 (enExample) 2022-08-15
JP7565271B2 JP7565271B2 (ja) 2024-10-10

Family

ID=67847672

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021528490A Active JP7565271B2 (ja) 2018-07-26 2019-07-25 ガンマ-デルタt細胞およびナチュラルキラー細胞の治療的調製物ならびに製造および使用する方法

Country Status (9)

Country Link
US (2) US20200032211A1 (enExample)
EP (1) EP3827074A2 (enExample)
JP (1) JP7565271B2 (enExample)
KR (1) KR102883631B1 (enExample)
CN (1) CN112912494B (enExample)
AU (1) AU2019311290B2 (enExample)
CA (1) CA3106056A1 (enExample)
SG (1) SG11202100320QA (enExample)
WO (1) WO2020021045A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11293021B1 (en) 2016-06-23 2022-04-05 Inscripta, Inc. Automated cell processing methods, modules, instruments, and systems
US9982279B1 (en) 2017-06-23 2018-05-29 Inscripta, Inc. Nucleic acid-guided nucleases
US10011849B1 (en) 2017-06-23 2018-07-03 Inscripta, Inc. Nucleic acid-guided nucleases
MX2019015505A (es) 2017-06-30 2020-07-28 Inscripta Inc Metodos, modulos, instrumentos y sistemas de procesamiento de celulas automatizados.
US10557216B2 (en) 2018-04-24 2020-02-11 Inscripta, Inc. Automated instrumentation for production of T-cell receptor peptide libraries
US10858761B2 (en) 2018-04-24 2020-12-08 Inscripta, Inc. Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells
IL292273B2 (en) 2018-08-14 2023-10-01 Inscripta Inc Devices, modules and methods for improved detection of edited sequences in living cells
US11142740B2 (en) 2018-08-14 2021-10-12 Inscripta, Inc. Detection of nuclease edited sequences in automated modules and instruments
US11214781B2 (en) 2018-10-22 2022-01-04 Inscripta, Inc. Engineered enzyme
CN109517793B (zh) * 2018-11-30 2022-05-10 广州长峰生物技术有限公司 一种NK细胞和γδT细胞共培养的建立方法
US11001831B2 (en) 2019-03-25 2021-05-11 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
AU2020247900A1 (en) 2019-03-25 2021-11-04 Inscripta, Inc. Simultaneous multiplex genome editing in yeast
EP3953477A4 (en) 2019-06-06 2022-06-22 Inscripta, Inc. HARDENING FOR RECURSIVE NUCLEIC ACID-DRIVEN CELL EDITING
US11203762B2 (en) 2019-11-19 2021-12-21 Inscripta, Inc. Methods for increasing observed editing in bacteria
WO2021126886A1 (en) 2019-12-18 2021-06-24 Inscripta, Inc. Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells
GB202000934D0 (en) * 2020-01-22 2020-03-04 Ucl Business Ltd Engineered immune cells
CN115135370A (zh) 2020-01-27 2022-09-30 因思科瑞普特公司 电穿孔模块和仪器
US20210238535A1 (en) * 2020-02-02 2021-08-05 Inscripta, Inc. Automated production of car-expressing cells
US20230134704A1 (en) * 2020-02-19 2023-05-04 Annelise E. Barron A method of treating cancer by upregulating cathelicidin gene expression and infusing natural killer cells
KR20220148859A (ko) * 2020-02-28 2022-11-07 에이브이엠 바이오테크놀로지, 엘엘씨 림프구 집단 및 이를 생산하는 방법
US20210332388A1 (en) 2020-04-24 2021-10-28 Inscripta, Inc. Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells
US11787841B2 (en) 2020-05-19 2023-10-17 Inscripta, Inc. Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli
US12648995B2 (en) * 2020-06-30 2026-06-09 Nanjing IASO Biotechnology Co., Ltd. Fully humanized bispecific chimeric antigen receptor targeting CD19 and CD22 and use thereof
GB202013962D0 (en) * 2020-09-04 2020-10-21 Gammadelta Therapeutics Ltd Immunotherapy composition
EP4214314A4 (en) 2020-09-15 2024-10-16 Inscripta, Inc. Crispr editing to embed nucleic acid landing pads into genomes of live cells
CN112300992B (zh) * 2020-10-27 2023-05-23 杜德(江门)生物科技有限公司 一种nk细胞培养液及多级激活nk细胞的培养方法
US11512297B2 (en) 2020-11-09 2022-11-29 Inscripta, Inc. Affinity tag for recombination protein recruitment
WO2022109477A1 (en) * 2020-11-23 2022-05-27 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
IT202000030266A1 (it) * 2020-12-10 2022-06-10 Ospedale Pediatrico Bambino Gesù Car t cells for treating cd19+, cd20+ or cd22+ tumors.
CN112501127B (zh) * 2020-12-21 2023-10-10 广东昭泰细胞生物科技有限公司 一种重编程nk细胞的培养方法
CA3204158A1 (en) 2021-01-04 2022-07-07 Juhan Kim Mad nucleases
WO2022150269A1 (en) 2021-01-07 2022-07-14 Inscripta, Inc. Mad nucleases
US11884924B2 (en) 2021-02-16 2024-01-30 Inscripta, Inc. Dual strand nucleic acid-guided nickase editing
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
WO2022233956A1 (en) 2021-05-05 2022-11-10 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CA3228168A1 (en) * 2021-08-03 2023-02-09 Gammadelta Therapeutics Ltd Engineering of gamma delta t cells and compositions thereof
CN113667640B (zh) * 2021-08-27 2022-09-02 广州百暨基因科技有限公司 CAR-γδT细胞的制备方法
GB202115389D0 (en) * 2021-10-26 2021-12-08 XNK Therapeutics AB Methods
EP4183871A1 (en) * 2021-11-23 2023-05-24 Université d'Aix-Marseille Process for preparing a composition comprising a combined cell population
CN114107200B (zh) * 2021-11-29 2023-04-21 华东师范大学 一种高纯度CD56+γδT细胞及其制备方法和用途
GB202204926D0 (en) * 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
EP4602152A1 (en) * 2022-10-10 2025-08-20 Kite Pharma, Inc. New large scale car-t immune cell manufacturing method utilizing lentiviral vector transfection
CN115651903B (zh) * 2022-11-14 2023-03-17 四川新生命干细胞科技股份有限公司 高杀伤力的免疫细胞群及其培养方法、试剂组合物和应用
EP4634233A2 (en) * 2022-12-13 2025-10-22 Dana-Farber Cancer Institute, Inc. Checkpoint modulators for enhancing immunotherapy
AU2024210701A1 (en) * 2023-01-17 2025-07-31 Ansun Biopharma, Inc. Methods of producing gamma delta t cells
WO2025046256A1 (en) * 2023-08-31 2025-03-06 Universite D'aix-Marseille Process for preparing a composition comprising a combined cell population
IT202400014212A1 (it) * 2024-06-20 2025-12-20 St Giannina Gaslini Prodotto per la terapia cellulare avanzata
ES3034332B2 (es) * 2025-05-21 2026-05-08 Univ Madrid Complutense Método de expansión selectiva in vitro y adquisición de fenotipo residente en tejido decélulas T Yo Vo1+ derivadas de sangre periférica

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1317108B1 (it) 2000-12-06 2003-05-26 Philogen Srl Processo per la selezione di frammenti anticorporali anti-angiogenesi,frammenti anticorpali anti-angiogenesi cosi' ottenuti e loro uso.
JP2010220479A (ja) * 2007-06-15 2010-10-07 Medeinetto:Kk Nk細胞の培養方法及びnk細胞の利用
EP2710123B1 (en) * 2011-05-19 2017-07-12 Instituto de Medicina Molecular Cell line of lymphocytes comprising gamma-delta t cells, composition and production method thereof
RU2751362C2 (ru) * 2014-12-29 2021-07-13 Новартис Аг Способы получения экспрессирующих химерный антигенный рецептор клеток
US10829735B2 (en) * 2015-07-21 2020-11-10 The Trustees Of The University Of Pennsylvania Methods for improving the efficacy and expansion of immune cells
CN118421557A (zh) * 2016-05-12 2024-08-02 阿迪塞特治疗公司 选择性扩增γδT细胞群的方法及其组合物

Similar Documents

Publication Publication Date Title
ES2240962T3 (es) Metodo para estimular selectivamente la proliferacion de celulas t.
JP2021530236A5 (enExample)
Playoust et al. Germinal center-dependent and-independent immune responses of tumor-infiltrating B cells in human cancers
JP5607357B2 (ja) 抗原特異的b細胞のクローン集団を獲得するための培養方法
ES2569240T3 (es) Polipéptidos y anticuerpos obtenidos a partir de células de leucemia linfocítica crónica y usos de los mismos
JP2020202867A (ja) キメラ受容体及びその使用方法
JP2022512913A (ja) 遺伝子操作されたt細胞を作製するための方法
Hillerdal et al. Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice
JP2017528133A (ja) T細胞またはnk細胞を活性化および増加させるための、可溶性抗体複合体
JP2018008949A (ja) 新規モジュレーターと使用の方法
JP2017514787A (ja) Aprilバリアント
EP1819830A2 (en) Methods for antibody engineering
JP2021513337A5 (enExample)
JP2014518080A (ja) 細胞のスクリーニング方法
CN107428827A (zh) 通过b细胞淘选和增殖高通量产生单克隆抗体
US20230181641A1 (en) Process for producing donor-batched cells expressing a recombinant receptor
Hohlfeld et al. Reflections on the “intrathymic pathogenesis” of myasthenia gravis
US20260132201A1 (en) METHODS FOR ENHANCING TCRab+ CELL DEPLETION EFFICIENCY
JP2023169422A (ja) 結合ポリペプチドおよびそれを作製する方法
US20230257462A1 (en) Methods for selective expansion of delta-3 gamma delta t-cell populations and compositions thereof
US20210290672A1 (en) Regulation of tumor-associated t cells
JP2022510387A5 (enExample)
WO2011048369A1 (en) Prognostic, screening and treatment methods and agents for treatment of metastasis and inflammation using t54 oncofoetal glycoprotein
JP2026505362A (ja) Cd4+およびcd8+一重陽性t細胞、ならびにこれを生成するための組成物および方法
JP5686600B2 (ja) 新規モノクローナル抗体とその用途